To this point, NSAIDS, particularly COX-2 inhibitors, have been proven to offer the greatest possibility for reducing CRC risk, either alone or in combination with other drugs [5], while it has been reported an elevated risk of serious cardiovascular events related with the administration of COX-2 inhibitors [10, 11]. The gene discussed is PTGS2; the disease is colorectal carcinoma.